Literature DB >> 16899463

Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.

Ziying Yan1, Diana C M Lei-Butters, Xiaoming Liu, Yulong Zhang, Liang Zhang, Meihui Luo, Roman Zak, John F Engelhardt.   

Abstract

The choice of adeno-associated virus serotypes for clinical applications is influenced by the animal model and model system used to evaluate various serotypes. In the present study, we sought to compare the biologic properties of rAAV2/1, rAAV2/2, and rAAV2/5 transduction in polarized human airway epithelia using viruses purified by a newly developed common column chromatography method. Results demonstrated that apical transduction of human airway epithelia with rAAV2/1 was 100-fold more efficient than rAAV2/2 and rAAV2/5. This transduction profile in human airway epithelia (rAAV2/1 >> rAAV2/2 = rAAV2/5) was significantly different from that seen following nasal administration of these vectors to mouse lung (rAAV2/5 > rAAV2/1 >> rAAV2/2), emphasizing differences in transduction of these serotypes between these two species. In stark contrast to rAAV2/2 and rAAV2/5, rAAV2/1 transduced both the apical and basolateral membrane of human airway epithelia with similar efficiency. However, the overall level of transduction across serotypes did not correlate with vector internalization. We hypothesized that differences in post-entry processing of these serotypes might influence the efficiency of apical transduction. To this end, we tested the effectiveness of proteasome inhibitors to augment nuclear translocation and gene expression from the three serotypes. Augmentation of rAAV2/1 apical transduction of human polarized airway epithelia was 10-fold lower than that for rAAV2/2 and rAAV2/5. Cellular fractionation studies demonstrated that proteasome inhibitors more significantly enhanced rAAV2/2 and rAAV2/5 translocation to the nucleus than rAAV2/1. These results demonstrate that AAV1 transduction biology in human airway epithelia differs from that of AAV2 and AAV5 by virtue of altered ubiquitin/proteasome sensitivities that influence nuclear translocation.

Entities:  

Mesh:

Year:  2006        PMID: 16899463      PMCID: PMC1712671          DOI: 10.1074/jbc.M604099200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts.

Authors:  J Hansen; K Qing; H J Kwon; C Mah; A Srivastava
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  Recent developments in recombinant AAV-mediated gene therapy for lung diseases.

Authors:  Terence R Flotte
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

Review 3.  New recombinant serotypes of AAV vectors.

Authors:  Guangping Gao; Luk H Vandenberghe; James M Wilson
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

4.  rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion.

Authors:  Wei Ding; Liang N Zhang; Charles Yeaman; John F Engelhardt
Journal:  Mol Ther       Date:  2006-01-25       Impact factor: 11.454

5.  Enhancing rAAV vector expression in the lung.

Authors:  Isabel Virella-Lowell; Benjamin Zusman; Kevin Foust; Scott Loiler; Thomas Conlon; Sihong Song; Kye A Chesnut; Thomas Ferkol; Terence R Flotte
Journal:  J Gene Med       Date:  2005-07       Impact factor: 4.565

Review 6.  Current development of adeno-associated viral vectors.

Authors:  G Romano
Journal:  Drug News Perspect       Date:  2005-06

7.  Species-specific differences in mouse and human airway epithelial biology of recombinant adeno-associated virus transduction.

Authors:  Xiaoming Liu; Ziying Yan; Meihui Luo; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

8.  Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

Authors:  J A Wagner; A H Messner; M L Moran; R Daifuku; K Kouyama; J K Desch; S Manley; A M Norbash; C K Conrad; S Friborg; T Reynolds; W B Guggino; R B Moss; B J Carter; J J Wine; T R Flotte; P Gardner
Journal:  Laryngoscope       Date:  1999-02       Impact factor: 3.325

9.  Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.

Authors:  D Duan; Y Yue; Z Yan; J Yang; J F Engelhardt
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

10.  Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.

Authors:  J Zabner; M Seiler; R Walters; R M Kotin; W Fulgeras; B L Davidson; J A Chiorini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

View more
  29 in total

1.  Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction.

Authors:  Paul M Kaminsky; Nicholas W Keiser; Ziying Yan; Diana C M Lei-Butters; John F Engelhardt
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

2.  Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo.

Authors:  Ziying Yan; Diana C M Lei-Butters; Yulong Zhang; Roman Zak; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

3.  AAV-6 mediated efficient transduction of mouse lower airways.

Authors:  Wuping Li; Liqun Zhang; Zhijian Wu; Raymond J Pickles; R Jude Samulski
Journal:  Virology       Date:  2011-07-14       Impact factor: 3.616

4.  Comparative biology of rAAV transduction in ferret, pig and human airway epithelia.

Authors:  X Liu; M Luo; C Guo; Z Yan; Y Wang; J F Engelhardt
Journal:  Gene Ther       Date:  2007-08-30       Impact factor: 5.250

5.  Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions.

Authors:  Ziying Yan; Xingshen Sun; Idil A Evans; Scott R Tyler; Yi Song; Xiaoming Liu; Hongshu Sui; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2013-09       Impact factor: 5.695

6.  Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

Authors:  Cathryn S Mah; Darin J Falk; Sean A Germain; Jeffry S Kelley; Melissa A Lewis; Denise A Cloutier; Lara R DeRuisseau; Thomas J Conlon; Kerry O Cresawn; Thomas J Fraites; Martha Campbell-Thompson; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

7.  Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells.

Authors:  Nicholas W Keiser; Ziying Yan; Yulong Zhang; Diana C M Lei-Butters; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

8.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

9.  Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.

Authors:  Ziying Yan; Xingshen Sun; Zehua Feng; Guiying Li; John T Fisher; Zoe A Stewart; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2015-04-20       Impact factor: 5.695

10.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.

Authors:  Wuping Li; Liqun Zhang; Jarrod S Johnson; Wu Zhijian; Joshua C Grieger; Xiao Ping-Jie; Lauren M Drouin; Mavis Agbandje-McKenna; Raymond J Pickles; R Jude Samulski
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.